Leo Pharma's new drug for atopic dermatitis receives EU approval

Leo Pharma received a recommendation from the expert panel of the European Medicines Agency in April, and the commission has followed this advice, approving the eczema treatment Adtralza from the Danish company.

Photo: Leo Pharma / PR

Now, Leo Pharma can get properly started on launching the drug Adtralza in the EU.

Tuesday, the EU Commission ratified the former recommendation for approval, which the Committee for Medicinal Products for Human Use (CHMP) gave Adtralza in April, according to a press release from the company.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs